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The PI3K/Akt signaling pathway, Notch, and other
oncogenes cooperate in the induction of aggressive
cancers. Elucidating how the PI3K/Akt pathway
facilitates tumorigenesis by other oncogenes may
offer opportunities to develop drugs with fewer side
effects than those currently available. Here, using
an unbiased in vivo chemical genetic screen in
Drosophila, we identified compounds that inhibit
the activity of proinflammatory enzymes nitric oxide
synthase (NOS) and lipoxygenase (LOX) as selective
suppressors of Notch-PI3K/Akt cooperative onco-
genesis. Tumor silencing of NOS and LOX signaling
mirrored the antitumor effect of the hit compounds,
demonstrating their participation in Notch-PI3K/
Akt-induced tumorigenesis. Oncogenic PI3K/Akt
signaling triggered inflammation and immunosup-
pression via aberrant NOS expression. Accordingly,
activated Notch tumorigenesis was fueled by
hampering the immune response or by NOS overex-
pression to mimic a protumorigenic environment.
Our lead compound, the LOX inhibitor BW B70C,
also selectively killed human leukemic cells by damp-
ening the NOTCH1-PI3K/AKT-eNOS axis.
INTRODUCTION
Tumorigenesis requires cooperative action among two or more
signaling pathways or genes, but the basis of cooperation often
remains undefined. Concurrent activation of Notch and phos-
phatidylinositol 3-kinase (PI3K)/Pten/Akt pathways can trigger
tumorigenesis in flies and mice (Palomero et al., 2007; Piovan
et al., 2013; Hales et al., 2014; Kwon et al., 2016). This oncogenic
combination is also prevalent in aggressive cancers in humans
(Eliasz et al., 2010; Kwon et al., 2016; Muellner et al., 2011),
such as pediatric T cell acute lymphoblastic leukemia (T-ALL)
(Palomero et al., 2007; Gutierrez et al., 2009). Although NotchCell R
This is an open access article under the CC BY-Nand PI3K/Akt inhibitors effectively kill cancer cells, only their
combination can bypass single-agent pathway inhibitor resis-
tance (Hales et al., 2014). Unfortunately, these pathways have
many physiological functions (Bray, 2016; Engelman, 2009;
Fruman and Rommel, 2014; Kopan and Ilagan, 2009), so the
systemic inhibition of Notch or PI3K/Akt results in severe and
lasting side effects (Akinleye et al., 2013; Ntziachristos et al.,
2014). Therefore, to minimize side effects, drugs that dampen
oncogenic interactions more selectively are needed.
The fruit flyDrosophila is a suitable genetic model for exploring
themolecular mechanisms of cancer (Bangi, 2013; Pagliarini and
Xu, 2003; Ferres-Marco et al., 2006; Vidal and Cagan, 2006;
Palomero et al., 2007) and for developing drugs using pheno-
type-based screening approaches (Dar et al., 2012; Gladstone
and Su, 2011; Gonzalez, 2013;Markstein et al., 2014;Willoughby
et al., 2013; Bangi et al., 2016). Here, using a Drosophila cancer
model (Palomero et al., 2007) to screen the Library of Pharmaco-
logically Active Compounds (LOPAC1280), we have identified
compounds capable of suppressing Notch-PI3K/Akt coopera-
tive tumorigenesis. Notch inhibitors impeded the development
of these tumors, but this was accompanied by high animal
mortality and notched wings—two effects characteristic of
Notch deficiency. However, we found many other compounds
capable of blocking tumor formation by this oncogene coopera-
tion without side effects. These include the anti-inflammatory
drug BWB70C (our top hit compound, which suppressed tumor-
igenesis with the lower dose), a lipoxygenase (LOX) inhibitor, and
drugs inhibiting nitric oxide (NO) production.
NO is generated by nitric oxide synthase (NOS) and is a key
signaling molecule in inflammation, immune response, and can-
cer (Fukumura et al., 2006). Arachidonate metabolites produced
by LOX enzymes are also primary mediators of inflammation
(Dennis and Norris, 2015) and cancer (Chen et al., 2009, 2014;
Wang and Dubois, 2010; Greene et al., 2011; Steinhilber et al.,
2010). Inflammation is an important contributing factor to solid
cancer associated with infection and autoimmunity (Coussens
and Werb, 2002) and with certain oncogenes (e.g., Myc
and Ras) (Mantovani et al., 2008). Therefore, it is particularly
important to understand the interplay between these inflamma-
tory mediators and Notch-PI3K/Akt cooperative oncogenesis.eports 22, 2541–2549, March 6, 2018 ª 2018 The Author(s). 2541
C-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Figure 1. Drug Screen Selectively Targeting Notch-PI3K/Akt Cooperative Oncogenesis
(A) Larval eye imaginal discs (upper row) and adult eyes (lower row) of the control and two tumor models, involving co-overexpression of Dl and either Akt or
Pten-RNAi (BL25967) using ey-Gal4 (ey >). Below: example of the adult resulting from GSI (DAPT)-treated, tumor-bearing larva. The side effect (notched wings)
mimics genetic Notch pathway inhibition.
(B) Schematic of the screen design. Tumor-bearing larvae (non-GFP) were treatedwith compounds (100 mg/mL in the food) or vehicle. Below: representative adult
fly ey > Dl > Akt treated with the top hit compound BW B70C during the larval stage.
(C) Heatmap of the screen results (right column, mean effect). Green, suppression; red, enhancement; gray, no significant change. Arrows point to anticancer
drugs in the LOPAC1280. n, number of larvae per drug per round (R).In vertebrates, the expression of inflammatory markers such
as reactive oxygen species, NO, and macrophage infiltration
are hallmarks of inflammation in cancer (Colotta et al., 2009;
Mantovani et al., 2008). In Drosophila, inflammation contributes
to adult gut tumorigenesis (Petkau et al., 2017), and both LOX
(Miller et al., 1994; Merchant et al., 2008; Stanley, 2006) and
NO (Nappi et al., 2000) pathways participate in general inflam-
matory responses to infection and/or epithelial tissue repair
(Wood and Martin, 2017). However, whether Drosophila NOS
and LOX have a role in tumorigenesis was unknown. To address
this, we genetically validated the contribution of the NOS and
LOX pathways and inflammation in Notch-PI3K/Akt-driven
tumorigenesis. Furthermore, we provide proof-of-concept evi-
dence that BWB70C blocks tumorigenesis in human T-ALL cells
by dampening a conserved NOTCH1-PI3K/AKT-eNOS axis.
RESULTS
Unbiased Drug Screen for Targeting Notch-PI3K/Akt
Oncogenic Cooperation
We devised a phenotype-based chemical screen to identify
agents that blockNotch-PI3K/Akt oncogenic cooperationwithout
harming normal cells. We used our Drosophila eye cancer model,
which captures themolecular features ofNotch-PI3K/Akt cooper-
ative oncogenesis (Figures 1A and S1A) (Palomero et al., 2007).
The Notch ligand Delta (Dl) is co-expressed with Akt or with an
RNAi transgene to silence Pten, a PI3K-negative regulator, using
the eye-specific promoter eyeless (ey)-Gal4. The cooperative ac-2542 Cell Reports 22, 2541–2549, March 6, 2018tion of these pathways is what causes the development of eye
tumors, and the activation of either pathway alone is not sufficient
to promote tumorigenesis (Figure 1A) (Ferres-Marco et al., 2006;
Palomero et al., 2007). The ey > Dl > Akt and ey > Dl > Pten-RNAi
models yield a similar robust eye tumor phenotype (tumor
incidence, 70%) (Figures 1A and S1A), allowing the identification
of compounds that suppress or further enhance the tumor
phenotype. Systemic inhibition of Notch using the g-secretase
inhibitor N-[N-(3,5-difluorophenacetyl)-l-alanyl]-S-phenylglycine
t-butyl ester (DAPT) not only blocks tumorigenesis but also inter-
feres with normal growth, resulting in smaller notched wings and
lethality (Figures 1A and S1B). Systemic inhibition of PI3K/Akt
signaling using LY294002 or wortmannin also resulted in high
lethality (Figure S1B), indicating toxic side effects comparable
to those seen in mice and humans (Muellner et al., 2011).
We screened the LOPAC1280 library of 1,280 small molecules,
including a set of U.S. Food and Drug Administration (FDA)-
approved anticancer drugs as internal controls. An annotated
list of the known targets of the LOPAC1280 drugs is readily
available, enabling the transformation of phenotypic screening
results into a target-based drug discovery approach (Jones
and Bunnage, 2017). We administered each drug in food during
the larval period at a concentration of 100 mg/mL in three double-
blind rounds (Rs) and then assessed the impact on tumorigen-
esis and normal tissue growth in adults (Figure 1B). This allowed
us to directly evaluate responses and side effects. Antitumor
response was calculated as the ratio of non-tumor eyes to
tumor eyes in treated flies, normalized to the vehicle control
Figure 2. NOS Facilitates Notch-Induced
Tumorigenesis
(A) Tumor incidence (as a percentage) in control
flies and after pharmacological or genetic inhibi-
tion or activation of NOS. Below: representative
images of control and L-NAME-treated eyes.
(B) Schematic of NO pathway and antitumorigenic
drugs identified in our screen and RNAi-based
validation.
(C) Tumor incidence (as a percentage, left graph)
and normalized survival (right graph) in RNAi-
silenced flies (n = 50–100 eyes/genotype).
(D) Tumor incidence (as a percentage) in flies co-
expressing Dl and NOS. Below: representative
images of control and BW B70C-treated animals.
(E) Tumor incidence (as a percentage) in Notch-
pipsqueak (psq) lola (eyeful cancer) flies with or
without trichostatin A (TSA) or BW B70C treat-
ment.
Mean ±SD. *p < 0.05, **p < 0.01, ***p < 0.001 (one-
way ANOVA followed by Bonferroni’s multiple
comparisons test).group (Figure S1C). Compounds that showed a lethal effect in R1
(n = 30 larvae/drug) were re-tested at lower doses (20 mg/mL).
After R1, any compound causing a response greater than 20%
was re-screened (198 suppressor and 276 enhancer com-
pounds) (Figure S1D) using a larger number of animals (n = 60
larvae/drug/R). This significantly reduced the number of false
positives and increased reproducibility (>80%) between R2
and R3 (Figure 1C). After screening approximately 100,000 tu-
mor-bearing flies, we found 90 compounds (Figure 1C) that
strongly (>60% response) suppressed (61) or enhanced (29)
tumorigenesis (see representative eyes and wings in Figures
1A and 1B to compare responses and side effects of DAPT
and BW B70C) (Tables S1 and S2). All positive hits were
counter-screened in larvae with single oncogene overexpres-
sion; none of them rescued single Dl- or Akt-induced pheno-Cell Retypes (data not shown), indicating that
the identified drugs target the coopera-
tive action of Notch and Akt.
Our screen identified 15of the 21 known
anticancer compounds included in the
library (Figure 1C; Table S3) as strong (13)
and moderate (2) suppressors of tumori-
genesis. Of the remaining 6, 2 were strong
enhancers, 2 were lethal, and 2 had no
effect. We were able to single out these
anticancer drugs, some of which are
approved by the FDA for the treatment of
leukemia and solid cancers, thus confirm-
ing the validity of our screen. These results
show a strong positive correlation with the
response observed in human cells.
RNAi-Based Validation of Drug
Screen Results
The remaining 48 strong suppressors
(excluding the 13 known anticancerdrugs) are previously unappreciated modulators of Notch-
PI3K/Akt-driven tumorigenesis. Because most compounds
have a known human molecular target, we validated these re-
sults genetically by examining whether tumor-specific RNAi
downregulation of candidate target genes (Figures S2A and
S3A) mimicked the action of the corresponding compounds.
We targeted 92 RNAi lines corresponding to 77 ortholog genes
of the annotated and predicted molecular targets of the hit com-
pounds (Table S4). We reasoned that an antineoplastic effect
would also rescue tumor-associated lethality. PI3K-RNAi was
used as a blind positive control, and effects were assessed in
adult flies. As a result, we confirmed that 64% of the compounds
act through conserved targets rather than indirect side effects
(Figures S2B and S2C). This indicates that despite the evolu-
tionary distance of Drosophila from humans, we can use ourports 22, 2541–2549, March 6, 2018 2543
Figure 3. Genetic Targeting of LOX Signaling Blocks Notch-PI3K/Akt Cooperative Oncogenesis
(A) Schematic LOX signaling pathway. Left labels: antitumorigenic drugs identified in our screen and RNAi-based silenced genes. Right labels: homologous
Drosophila genes. In response to inflammatory stimuli, PLA2 releases arachidonic acid (AA) and/or linoleic acid (LA) from themembrane phospholipids, which are
converted to a variety of bioactive lipids via LOX enzymes.
(B) Tumor incidence (left) and normalized survival to adulthood (right) of control and ey > Dl > Pten-RNAi flies after depleting the indicated genes via RNAi or
mutation. PI3K92E-RNAi is the internal positive control. n = 50–100 eyes/genotype.
(C) Example eyes of ey > Dl > Pten-RNAi without or with depleted PI3K92E or GXIVsPLA2 via RNAi.
Mean ± SD. *p < 0.05, **p < 0.01, ***p < 0.001 (one-way ANOVA followed by Bonferroni’s multiple comparisons test).Drosophila-based strategy to identify anticancer drugs, as well
as their clinically relevant targets.
PI3K/Akt Fuels Notch-Driven Tumorigenesis through
NOS
A survey of the hit compounds classified as strong to moderate
suppressors revealed the presence of numerous anti-inflamma-
tory agents targeting the NO/NOS and LOX signaling pathways
(Table S1), including BW B70C and nordihydroguaiaretic acid
(NDGA), each ofwhich inhibits 5- and 12/15-LOX enzymes (Payne
et al., 1991; Hussey and Tisdale, 1996; Rudhard et al., 2015).
BWB70C drew considerable attention because it blocked tumor-
igenesis at a very low dose (20 mg/mL) (Figure 1B; Table S1),
especially compared with DAPT (Figures 1A and S1A).
We first investigated how NO signaling contributes to
Notch-PI3K/Akt-induced tumorigenesis. Using the NOS
reporter NOSMI09718 (Venken et al., 2011), we observed
aberrant expression of NOS within the tumor eye tissue
(Figure S3B), an action induced by Pten depletion (Figures
S3A and S3C). Treatment of ey > Dl > Pten-RNAi larvae with2544 Cell Reports 22, 2541–2549, March 6, 2018N(G)-nitro-L-arginine methyl ester (L-NAME), a selective NOS
inhibitor with documented activity in Drosophila (Mukherjee
et al., 2011), significantly suppressed tumor growth (Figure 2A).
Similarly, genetic silencing of the single Drosophila NOS gene
(ey > Dl > Pten-RNAi > NOS-RNAi) or a NOS endogenous
mutation (ey > Dl > Pten-RNAi; NOSMI09718/+) selectively sup-
pressed tumorigenesis (Figures 2A and S2C).
Moreover, targeting the NO canonical pathway within tumor
cells by RNAi silencing of genes encoding soluble guanylyl
cyclases (sGC-a and sGC-b), cyclic guanosine monophosphate
(cGMP)-PKG21D, and its target, myosin light-chain kinase
(Mlck), suppressed tumorigenesis (Figures 2B and 2C).
These results validate another of the top hit compounds that
we identified in our screen: ML-7, an inhibitor of Mlck (Figures
2B and 2C). Altogether, we found that NOS was aberrantly
expressed in tumor cells and that tumor cell-specific knock-
down of NO signaling suppressed tumorigenesis. These
results highlight the importance of the NO-sGC/cGMP/PKG
(cGMP-dependent protein kinase G) pathway in Notch-PI3K/
Akt-driven tumorigenesis.
Figure 4. Tumor-Associated Hemocytes
and Response to LOX Inhibitor
(A) Hemocytes (arrowhead) in control eye discs
(ey >) are rounded and form clusters attached to
the disc epithelium.
(B) Representative hemocytes in a neoplastic
tumor disc with a migratory spindle shape (arrow).
(C) Hemocyte counts in the indicated genotypes
(n = 14 eye discs/genotype). Mean ± SD.
**p < 0.01, ***p < 0.001, ****p < 0.0001 (one-way
ANOVA followed by Bonferroni’s multiple
comparisons test).
(D) Hemocytes in a Notch-PI3K/Akt eye disc
treated with BW B70C (20 mg/mL, 63.2 mM). Right:
magnifications of the outlined area. Arrow and
arrowhead point to round (pancake-like) and
clustered hemocytes, respectively.
Tissue and tumor resident hemocytes are labeled
with GstD1-GFP (green, A and B), Hml-dsRed.D
(red, D), and DAPI (blue). For co-localization of
GstD1-GFP with the pan-hemocyte marker
Hml-dsRed.D, see Figure S4.Overexpression of NOS, together with overexpression of Dl,
induced tumorigenesis in the absence of further hyperactivation
of PI3K/Akt (ey > Dl > NOS) (Figure 2D). Eye-specific silencing or
overexpression of the NOS gene alone is inconsequential for
eye growth (Ca´ceres et al., 2011; Jaszczak et al., 2015). BW
B70C treatment blocked Notch-NOS-driven tumorigenesis
(Figure 2D), suggesting that this process involves an axis with
LOX/NOS interdependency. Conversely, tumors induced by
the cooperation of Notch with the epigenetic regulators
Pisqueak and Lola (Ferres-Marco et al., 2006) were not sensitive
to BW B70C, even though they could be suppressed using the
epigenetic drug trichostatin A (Figure 2E). Hence, BW B70C
does not generally suppress Notch-driven tumorigenesis
but dampens a tumor formation process orchestrated by inflam-
matory NOS.
LOX Pathway Inhibition Blocks Notch-PI3K/Akt-Driven
Tumorigenesis
LOX enzymatic activity and LOX-derived lipids have been de-
tected in Drosophila extracts and other insects, but the LOX
gene or genes remained undefined (Page´s et al., 1986; Tan
et al., 2016). We therefore searched for Drosophila LOX pathway
homologs that could be suitable for further validation of our
screen results.
Leukotriene A4 hydrolase (LTA4H) catalyzes the production
of leukotriene B4 (LTB4), a major lipid product of LOX enzymes
that is highly expressed in some cancers (Steinhilber et al.,
2010). The Drosophila gene CG10602 encodes an LTA4H
homolog (Figure 3A). Halving its gene dosage (ey > Dl >
Pten-RNAi > CG10602f04195/+) markedly suppressed tumori-
genesis and rescued tumor-associated lethality (Figures 3B
and S3A). Leukotrienes act through G protein-coupled recep-Cell Rtors (Wang and Dubois, 2010), and we
silenced the allatostatin receptors, the
structural orthologs of leukotriene recep-
tors in Drosophila (Figure 3A; Table S4).Inactivation of AstA-R1 suppressed tumorigenesis, whereas
silencing AstA-R2, AstC-R1, and AstC-R2 did not affect it
(Figure 3B).
Themost upstream step in LOX-mediated production of proin-
flammatory lipid metabolites is the release of arachidonic acid
from the plasma membrane, mediated by phospholipase A2
(PLA2) (Dennis and Norris, 2015) (Figure 3A). Five suppressor
drugs identified in our screen target this step (Figure 3A;
Table S1). We tested the seven predicted Drosophila PLA2
genes (Renault et al., 2002) and found that tumor-specific
RNAi silencing of GXIVsPLA2, as well as halving its gene dosage
(GXIVsPLA2f00744/+), strongly suppressed tumorigenesis (Fig-
ures 3B and 3C), mirroring the antitumor effect of the identified
drugs. This confirmed that LOX-generated lipids are required
for Notch-PI3K/Akt-driven tumors.
Protumorigenic Immune Inflammation Underlies Notch-
PI3K/Akt Cooperation
The participation of the NO/NOS and LOX pathways in Notch-
PI3K/Akt-promoted tumorigenesis hints at an unanticipated
connection between inflammation and this oncogenic coopera-
tion. Work in vertebrates has implicated macrophage infiltration
and expression of inflammatory markers such as NO as key
hallmarks of inflammation in solid cancer (Colotta et al., 2009;
Mantovani et al., 2008), and immune cells that infiltrate
tumors facilitate tumor growth or survival (Grivennikov et al.,
2010). In Drosophila, macrophage-like hemocytes (Lemaitre and
Hoffmann, 2007) have been implicated in the immune response
against epithelial tumors (Pastor-Pareja et al., 2008; Cordero
et al., 2010).
We examined the hemocytes associated with these tumors
using the hemocyte-specific marker Hml-dsRed.D (Makhijanieports 22, 2541–2549, March 6, 2018 2545
et al., 2011) and the oxidative stress reporter GstD1-GFP, which
we found is expressed in hemocytes (Figure S4A). Wild-type and
hyperplastic eye disc-associated hemocytes typically form
aggregates with a rounded morphology (Figures 4A, S4B, and
S4C) and are attached to the basal membrane (Cordero et al.,
2010). We observed that hemocytes within Notch-PI3K/Akt
discs were dispersed and became polarized (spindle shaped)
(Figures 4B, S4D, and S4E), infiltrating the tumor epithelium
(Figures 4C, S4F, and S4G). This suggests that hemocytes
change their morphology in response to signals from tumor cells.
Consistent with this idea, these morphological changes were
suppressed in mutant discs treated with BW B70C (Figures 4C
and 4D), suggesting that NOS/LOX activity shapes the inflamma-
tory response in Notch-PI3K/Akt tumors. Altogether, these data
link inflammation to tumorigenesis driven by these oncogenes.
Genetic Depletion of Prophenoloxidase in Immune Cells
Fuels Notch-Mediated Tumorigenesis
A salient feature of cancer-related inflammation is immunosup-
pression (Coussens and Werb, 2002; Mellman et al., 2011). In
Drosophila, melanization—a process mediated by the enzyme
phenoloxidase (PO) encoded by the prophenoloxidase (PPO)
genes—is a critical innate immune response to tumor cells
(Minakhina and Steward, 2006). Platelet-like crystal cells,
another class of hemocytes present in larval stages, are the
site of PPO gene synthesis (Binggeli et al., 2014). We examined
PPO expression and function to further investigate the participa-
tion of inflammation and immunosuppression in Notch-PI3K/Akt
tumorigenesis. Larvae with single Notch pathway overactivation
(ey > Dl) showed robust stimulation of PPO1 and PPO2 expres-
sion in immune cells (Figure 5A). Conversely, tumor-bearing
(ey > Dl > Pten-RNAi) and single PI3K/Akt (ey > Pten-RNAi)
larvae did not show this response (Figure 5A), suggesting that
activated PI3K/Akt signaling dampens a secreted signal
required in crystal cells to activate the immune response.
To ascertain the role of immune cell-derived PPO/PO in single
Dl-induced overgrowth, we created a genetic immunosup-
pressed condition using a triple PPO1, PPO1, PPO3 knockout
(Binggeli et al., 2014). Halving PPO gene dosage resulted
in 55% of the emerging adults bearing full-blown tumors
(ey > Dl, PPO1/+, PPO2/+, PPO3/+) (Figure 5B), equal to the
effect of NOS overexpression (Figure 2D). Reducing PPO in
Notch-PI3K/Akt larvae with already-low PPO levels did not
enhance tumorigenesis. Furthermore, we found that aberrant
NOS expression was sufficient to dampen PPO expression (Fig-
ure 5C) and the immune response triggered by the PO-acti-
vating cascade manifested as a strong reduction of melanized
crystal cell response after heat stress (Neyen et al., 2015) (Fig-
ures 5D and 5E) (see Supplemental Experimental Procedures).
Altogether, these observations indicate that immunosuppres-
sion is driven by aberrant NOS promoted by activated PI3K/
Akt in the tumor cells, which explains how activated PI3K/Akt
unleashes the oncogenic potential of Notch.
Validation in Human T Cell Acute Lymphoblastic
Leukemic Cells
We validated the antitumor effect of BW B70C in well-
established human T-ALL cell models that depend on2546 Cell Reports 22, 2541–2549, March 6, 2018NOTCH1 and PI3K/AKT signaling (Palomero et al., 2007). We
observed that BW B70C treatment killed T-ALL cells (Palomero
et al., 2007) that were resistant to Notch inhibitors (PTEN-
negative, g-secretase inhibitor [GSI]-resistant T-ALL cell lines
RPMI8402, CCRF-CEM, P12-ICHIKAWA, JURKAT, and
MOLT-3), as well as PTEN-positive, GSI-sensitive T-ALL lines
(CUTLL1, ALL-SIL, and DND-41) (Figure 5F). BW B70C
treatment had little or no toxicity against normal T lymphocytes
(peripheral blood mononucleated cells [PBMCs]) derived from
healthy donors (Figure 5F). Moreover, paralleling the results
obtained in Drosophila tumors, we found that one of the
three NOS genes, endothelial NOS (eNOS), was aberrantly
enriched in AKT/NOTCH1-driven T-ALL cells (Figure 5G).
Healthy PBMCs did not show eNOS expression (Figure 5H).
Finally, we found that BW B70C selectively killed T-ALL cells
associated with suppression of the aberrant eNOS in leukemic
cells (Figure 5H).
DISCUSSION
Several Notch and PI3K/Akt inhibitors with potent antineoplastic
activity are available, but their progress toward clinical use is
hindered by side effects associated with the inhibition of
physiological signaling and by drug resistance (Andersson and
Lendahl, 2014; Chia et al., 2015; Fruman and Rommel, 2014).
The characterization of the targets and mechanisms down-
stream of Notch-PI3K/Akt in tumorigenesis that are distinct
from their targets in normal cells is crucial for identifying cancer
vulnerabilities that could be exploited therapeutically. Using an
in vivo drug screen in Drosophila we have identified pharmaco-
logically active compounds that block Notch-PI3K/Akt-driven
tumors in flies and validated the top hit compound in human
T-ALL cells with NOTCH1 and PI3K/AKT mutations. In addition,
BWB70C and compounds inhibiting specific inflammatory path-
ways were found to elicit potent and selective antitumorigenic
responses in Notch-PI3K/Akt tumors by blocking a hitherto
unsuspected NOS/LOX axis. Our screen identified 15 of the 21
well-known anticancer compounds included as internal controls;
some of them have anti-inflammatory properties (Table S3), but
most act mainly by blocking cell proliferation non-specifically
through DNA damage.
Genetic studies further highlighted a strong requirement
for tumor-specific inflammation driven by LOX- and NOS-
dependent Notch-PI3K/Akt cooperation. Human LOX signaling
(Chen et al., 2009; Hussey and Tisdale, 1996) and NO signaling
(Fukumura et al., 2006; Lim et al., 2008) have been linked to spe-
cific cancers as both tumor suppressors and tumor enhancers.
Here we linked these inflammatory pathways to tumor initiation
by Notch-PI3K/Akt cooperation. The oncogenes Ret, Myc, and
Ras can trigger an intrinsic inflammatory response that creates
a protumorigenic microenvironment (Mantovani et al., 2008),
which accelerates cancer development (Grivennikov et al.,
2010). We found that activated PI3K/Akt signaling triggers
inflammation and immunosuppression via aberrantNOS expres-
sion. Overexpressing NOS or diminishing the endogenous
immune response is sufficient to facilitate tumor initiation via
the activated Notch pathway, supporting the notion that inflam-
mation is a key mechanism to unleash the oncogenic potential of
Figure 5. Immunosuppression Releases Notch Oncogenic Potential
(A) PPO gene expression in immune cells attached to eye discs (n = 30/genotype) and whole larvae (n = 5/genotype). PPO3 was undetected in these assays.
Experiments were performed in triplicate.
(B) Relative tumor incidence (as a percentage) in ey > Dl; PPO1–PPO2/+ (n = 50–100 eyes). Below: representative eyes.
(C) PPO1 and PPO2 expression in control and tub > NOS larvae.
(D and E) Melanized crystal cell counts (D) and images (E, right, magnifications) of larvae with crystal cell-mediated PPO/PO activity (black cells) response to heat
shock. Negative control was PPO1–3.(F) BW B70C treatment in a panel of T-ALL cell lines and healthy PBMCs. Data represent three independent experiments
and are expressed as mean ± SD. Student’s t test for each T-ALL cell line response was ***p < 0.001. Mean ± SD. *p < 0.05, **p < 0.01, ***p < 0.001 (one-way
ANOVA followed by Bonferroni’s multiple comparisons test in B and Student’s t test in D).
(G)qRT-PCRanalysisof thethreeNOSgenesinT-ALLcells (relative toGADPH).Graphshowspooleddata fromthree independentexperimentsandrepresentsmean±SD.
(H) Representative western blots of three independent analyses showing eNOS levels in PBMCs and T-ALL cells treated with BW B70C (20 mg/mL, 48 hr) or DMSO
(vehicle).Notch. LOX/NOS inhibition did not harm normal cells, which
suggests that these pathways represent promising, safe, drug-
gable targets for human cancers.Validation of the anti-inflammatory drug BWB70C in a panel of
human T-ALL cells dependent on NOTCH1 and PI3K/AKT yet
resistant to Notch inhibitors (Palomero et al., 2007) furtherCell Reports 22, 2541–2549, March 6, 2018 2547
highlights the considerable value of unbiased chemical screens
in Drosophilawhen it comes to deciphering targets and potential
therapeutic approaches relevant to human cancers.
EXPERIMENTAL PROCEDURES
Drosophila Husbandry
The list of RNAi transgenesused is in Table S4.Other fly stocks usedwerew1118,
ey-Gal4, UAS-Dl, CyO twist-GFP, CyO tub-Gal80, Pten-RNAi (BL25967), UAS-
NOS (BL56830 and BL56823), GXIVsPLA2f00744, CG10602f04195, PnsEY05553,
AstA-R1MI14175 (y1 w*; Mi{MIC}AstA-R1MI14175), NOSMI09718 (y1 w*; Mi{MIC}
NosMI09718), and PKG/dg2MI02855 (y1 w*; Mi{MIC}dg2MI0285), all from the Bloo-
mington Drosophila Stock Center; PI3K92E-RNAi (GD11228, v38985) from the
Vienna Drosophila RNAi Center; GS(2)1D233C (dAkt1) (Palomero et al., 2007);
GS(2)88A8lola pipsqueak (the eyeful cancer strain) (Ferres-Marco et al., 2006);
PPOD1–2,3 (a gift from B. Lemaitre); GstD1-GFP (a gift from D. Bohmann); and
Hml-dsRed.D (FBtp0069700) (a gift from K. Brueckner). Flies were reared and
maintained in standard fly food at 27C on a 12-hr light/dark cycle.
Statistical Methods
All statistical analyses were performed in GraphPad Prism 6. qPCR data and
melanized crystal cell counts were analyzed using unpaired Student’s t tests.
For tumor incidence and hemocyte counts, p values were calculated using
one-way ANOVA followed by Bonferroni’s multiple comparison tests.
All research and human cell procedures were conducted in strict compli-
ance with the European Community Council Directives and Spanish legisla-
tion. The protocols were approved by the Universidad Miguel Herna´ndez
(2017/VSC/PEA/00154) at the Institute of Neuroscience.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
five figures, and four tables and can be found with this article online at
https://doi.org/10.1016/j.celrep.2018.02.049.
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